Table 4 Subgroup analysis of polymorphisms and survival.

From: Polymorphisms in PARP1 predict disease-free survival of triple-negative breast cancer patients treated with anthracycline/taxane based adjuvant chemotherapy

subgroup

variants

DFS

HR(95%CI)

P

Lymph node negative

rs1136410

TT

1(Ref)

 

TC

0.937(0.404–2.170)

0.879

CC

0.219(0.027–1.716)

0.148

Rs6664761

TT

1(Ref)

 

TC

0.435(0.161–1.180)

0.102

CC

0.261(0.088–0.778)

0.016

Rs7531668

TT

1(Ref)

 

TA

1.083(0.406–2.890)

0.873

AA

3.361(1.259–8.969)

0.015

Age ≤ 50

rs1136410

TT

1(Ref)

 

TC

0.683(0.353–1.319)

0.256

CC

1.073(0.498–2.315)

0.857

Rs6664761

TT

1(Ref)

 

TC

0.405(0.170–0.967)

0.042

CC

0.697(0.314–1.545)

0.374

Rs7531668

TT

1(Ref)

 

TA

0.530(0.243–1.154)

0.110

AA

1.711(0.785–3.731)

0.177

  1. Abbreviations: DFS, disease free survival; HR, hazard ratios; CI, confidence interval; Ref, reference; UK, unknown.
Back to article page